EQUASENS: Strong H1 2026 business performance: H1 revenue of €124.5 million (+7.3% on a reported basis) and ARR of €111.1 million at 30 June 2026 (+8.8% vs. 30 June 2025)
Equasens (EQS) reported H1 2026 revenue of €124.5m, up 7.3% reported basis, and ARR of €111.1m (+8.8% vs. 30 June 2025). Maintenance and subscriptions rose to €55.7m (+8.4%), and software and services to €21.7m (+24.9%). Growth was driven by PHARMAGEST and AXIGATE LINK integrations, with MEDICAL SOLUTIONS benefiting from EREVO.
How this was made
The 30-second read
Why it matters
The disclosed H1 revenue and ARR figures, plus segment-level drivers and integration/scope contributions, provide a concrete update to forward expectations and recurring revenue quality.
Market read
Fresh H1 financials with ARR growth and named operational drivers can shift near-term valuation expectations for recurring healthcare IT revenue.
What to watch
The article notes revenue includes scope changes (€6.3m) and Ségur Wave 2 is only €0.6m in H1, so traders may discount durability until H2 scaling is clearer.
Background
Equasens (EQS) is a digital healthcare solutions provider with divisions including PHARMAGEST, AXIGATE LINK, E-CONNECT, and MEDICAL SOLUTIONS.
Ticker impact
Equasens reported H1 2026 revenue of €124.5m (+7.3% reported) and ARR of €111.1m (+8.8%), with segment and acquisition contributions detailed.
Near-term bias positive as traders may re-rate recurring revenue durability and H2 execution confidence.
The article provides fresh, quantified H1 results (revenue, ARR) plus specific drivers (PHARMAGEST organic growth, EREVO integration, Ségur Wave 2 €0.6m) that can influence expectations for H2 2026.
Market effects
Supports the digital healthcare software and services theme in Europe, highlighting recurring revenue growth and government-program monetization (Ségur Wave 2).
Emphasizes France and Italy momentum (PHARMAGEST), with Germany and Belgium declines that may affect regional sentiment on healthcare IT spend.
Moderate, as it is company-specific but reinforces investor appetite for European healthcare IT recurring revenue stories.
Counterpoint
Systems and equipment were flat to slightly down (-0.3%) and E-CONNECT like-for-like declined (-17.4%), so growth may be uneven across product lines.
Key entities
- companyEquasens
Reported H1 2026 revenue €124.5m (+7.3% reported) and ARR €111.1m (+8.8%) with segment and acquisition drivers.
- programSégur Wave 2
French digital health programme; Wave 2 revenue contribution reported at €0.6m in H1 2026.
- acquisitionEREVO
MEDICAL SOLUTIONS acquisition contributing €3.9m (+22.4%) to software solutions and services revenue in H1.
